Virus News and Research

Latest Virus News and Research

Wellcome-Wolfson Capital Awards initiative invests over 30M in large-scale university infrastructure projects

Over -30 million is being invested into large-scale university infrastructure projects courtesy of the Wellcome-Wolfson Capital Awards initiative.

3 Jul 2010

Clemizole can yield high-level synergy with protease inhibitor class: Research

Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the lab of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues entitled, "The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole is Highly Synergistic with HCV Protease Inhibitors".

2 Jul 2010

Virus related to hepatitis C discovered in Asian bats

Viral hepatitis affects more than 500 million people worldwide and is a cause of liver failure and liver cancer. While vaccines are available for hepatitis A and B, this is not the case for hepatitis C, which affects as much as two percent of the population in the U.S. Scientists today are reporting discovery of a virus related to hepatitis C in Asian bats, which may provide insights into the origins of the hepatitis C virus and into the mechanisms by which infectious diseases move from other species to humans.

2 Jul 2010

Adding nutrients could improve efficiency of deep sea biological pump

Adding nutrients to the sea could decrease viral infection rates among phytoplankton and enhance the efficiency of the biological pump, a means by which carbon is transferred from the atmosphere to the deep ocean, according to a new mathematical modelling study. The findings, published in the Journal of Theoretical Biology, have implications for ocean geo-engineering schemes proposed for tackling global warming.

2 Jul 2010

New York Times: AIDS drug program has growing waiting list

The New York Times: "The weak economy is crippling the government program that provides life-sustaining antiretroviral drugs to people with H.I.V. or AIDS who cannot afford them. Nearly 1,800 have been relegated to rapidly expanding waiting lists that less than three years ago had dwindled to zero. ...

2 Jul 2010

AHF members urge Congress to honor AIDS funding commitment

Five AIDS treatment clients and medical care providers from Uganda are visiting Washington, DC for a series of over 50 meetings this week on Capitol Hill with Senate and Congressional leaders to lobby Congress to honor the US' landmark commitment to PEPFAR (the President's Emergency Plan for AIDS Relief), the successful US global AIDS program.

2 Jul 2010

SAIC-Frederick, Fluidigm collaborate to decode entire genome of Epstein-Barr virus

SAIC-Frederick, Inc. and Fluidigm Corporation are collaborating to decode the entire genome of the Epstein-Barr virus (EBV) using technology that can speed up research on the genetic basis of cancer and other diseases.

1 Jul 2010

Diagnostic Hybrids receives Chinese SFDA approval for D3 Ultra DFA Respiratory Virus Screening and ID Kit

Diagnostic Hybrids, a Quidel Company, received approval from the People's Republic of China's State Food and Drug Administration (SFDA) for its D3 Ultra DFA Respiratory Virus Screening and ID Kit. The D3 Ultra DFA Respiratory Virus Screening and ID Kit is a direct fluorescence assay (DFA) that provides rapid, sensitive and specific screening and identification of Influenza A, Influenza B, Parainfluenza 1, 2, & 3, Respiratory Syncytial Virus and Adenovirus.

1 Jul 2010

GeoVax Labs postpones proposed public offering

GeoVax Labs, Inc., a biotechnology company dedicated to developing vaccines that prevent and fight human immunodeficiency virus (HIV), today announced that it has decided to postpone its proposed public offering of units, each consisting of a share of common stock and a warrant to purchase another share.

1 Jul 2010

Cubist commences enrollment in Phase 2 study of CXA-201 for complicated intra-abdominal infections

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced the enrollment of the first patient in a Phase 2 study with CXA-201. This multicenter, double-blind, randomized, study will compare the safety and efficacy of intravenous CXA-201 with an active comparator in patients with complicated intra-abdominal Infections (cIAI). This international study is expected to enroll 120 patients.

1 Jul 2010

Cubist Phase 2 trial for efficacy of CXA-101 in complicated urinary tract infections meets objectives

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that the recently-completed Phase 2 study of CXA-101, a novel cephalosporin, compared to ceftazidime for the treatment of complicated urinary tract infections (cUTI) in adults met its study objectives.

30 Jun 2010

Sirnaomics receives NIH SBIR grants to advance siRNA therapeutics for critical human diseases

Sirnaomics, Inc. announced today that the company has received two SBIR (Small Business Innovation Research) grants from National Cancer Institute (NCI) and National Institute of Allergy and Infectious Diseases (NIAID), of National Institute of Health (NIH). Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to developing RNA interference (RNAi) therapeutics for treatment of critical human diseases.

30 Jun 2010

Original viral genetic sequences still present months after initial infection, says study

Scientists have been surprised to learn that, despite thousands of changes that viruses like HIV undergo in rapid fashion to evade the body's immune system, the original version that caused the infection is still present in the body months later.

30 Jun 2010

Greenwire/New York Times examine dengue vaccine development

Greenwire/New York Times reports on the growing number of cases of dengue worldwide, including the CDC's report last month that the virus has now been locally acquired in the continental U.S. for the first time in 65 years. "While a few cases were reported earlier, they were primarily in Americans who had caught the virus abroad or at the Texas-Mexico border," the news service writes.

30 Jun 2010

Alnylam receives Portuguese, Swedish, British approvals to initiate ALN-TTR01 Phase I study in ATTR

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that its applications for ALN-TTR01 have been given clearance by Portuguese, Swedish, and British regulatory authorities to begin clinical testing. The trial will begin enrolling patients shortly in a blinded, randomized, placebo-controlled, multicenter Phase I study.

29 Jun 2010

Routine testing of inmates can reduce HIV incidence in the U.S.

Routine, jail-based HIV testing of inmates can successfully identify a substantial proportion of people unknowingly infected with HIV and could play a critical role in preventing the spread of the disease, according to a new report in this week's U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.

29 Jun 2010

Mammalian embryo use different strategies to suppress retroviral infection: Study

Some viruses insert themselves into the host's DNA during infection in a process called retroviral integration, causing several diseases, including AIDS and cancer, notes a Texas A&M researcher who specializes in fetal diseases.

29 Jun 2010

LEAPS vaccine technology generates dendritic cells to stimulate immune system to fight viral illnesses

CEL-SCI Corporation and researchers at the Northeastern Ohio Universities Colleges of Medicine and Pharmacy (NEOUCOM) jointly announced today that a LEAPS-based vaccine (Ligand Epitope Antigen Presentation System) study has demonstrated the technology's potential using dendritic cells to stimulate the immune system to fight viral illnesses and other diseases.

29 Jun 2010

Study implicates cytokine molecule IL-17 in low back pain associated with herniated discs

An immune cell known to cause chronic inflammation in autoimmune disorders has been identified as a possible culprit in low back pain associated with herniated discs, according to doctors at Duke University Medical Center.

29 Jun 2010

Researchers study mechanism of human brain

Because of its intricate organization, figuring out the wiring diagram that explains how the billions of neurons in the brain are connected, and determining how they work together, remains a formidable task.

29 Jun 2010

Virus News and Research

Latest Virus News and Research

Wellcome-Wolfson Capital Awards initiative invests over 30M in large-scale university infrastructure projects

Clemizole can yield high-level synergy with protease inhibitor class: Research

Virus related to hepatitis C discovered in Asian bats

Adding nutrients could improve efficiency of deep sea biological pump

New York Times: AIDS drug program has growing waiting list

AHF members urge Congress to honor AIDS funding commitment

SAIC-Frederick, Fluidigm collaborate to decode entire genome of Epstein-Barr virus

Diagnostic Hybrids receives Chinese SFDA approval for D3 Ultra DFA Respiratory Virus Screening and ID Kit

GeoVax Labs postpones proposed public offering

Cubist commences enrollment in Phase 2 study of CXA-201 for complicated intra-abdominal infections

Cubist Phase 2 trial for efficacy of CXA-101 in complicated urinary tract infections meets objectives

Sirnaomics receives NIH SBIR grants to advance siRNA therapeutics for critical human diseases

Original viral genetic sequences still present months after initial infection, says study

Greenwire/New York Times examine dengue vaccine development

Alnylam receives Portuguese, Swedish, British approvals to initiate ALN-TTR01 Phase I study in ATTR

Routine testing of inmates can reduce HIV incidence in the U.S.

Mammalian embryo use different strategies to suppress retroviral infection: Study

LEAPS vaccine technology generates dendritic cells to stimulate immune system to fight viral illnesses

Study implicates cytokine molecule IL-17 in low back pain associated with herniated discs

Researchers study mechanism of human brain

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Newsletters you may be interested in